الفهرس 
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 137 |  |  |
| | | from | 137 | | |
Abstract
The knee joint represents one of the anatomical locations that most frequently suffer osteoarthritis (OA), which increases with age and has a prevalence of 15.6% in men and 30.7% in women over 55 years old . Osteoarthritis is a rheumatic disease that causes serious physical disability and leads to high living costs. There are several options for treating knee OA including non- pharmacological therapy, pharmacological treatment and interventional measures such as intra-articular infiltrations with corticosteroids or hyaluronic acid (HA) . In recent years, new treatments have been reported to be effective for treating patients with knee OA, including intra- articular platelet-rich plasma application, mesenchymal stem cells, ozone therapy, hypertonic dextrose and even the botulinum toxin type A. Intra-articular or extra-articular applications of hypertonic dextrose infiltration over ligament and tendon insertions have been used for decades to treat musculoskeletal pain under the name of Prolotherapy ; infiltrations are performed using hypertonic dextrose usually mixed with local anesthetics. Nevertheless, Hypertonic Dextrose Prolotherapy (HDP) remains of little use when treating knee OA; given the lack of solid scientific evidence to support its benefits, it has been classified as a complementary therapeutic intervention. Platelet-rich plasma (PRP) exists in this category. Platelets – besides contributing to the process of hemostasis – play different critical roles in the body. For example, following a tissue injury, platelets attract white blood cells to the site of injury and prevent damaged cells from being infected. Moreover, platelets contain a growth factor (ie, platelet.